In today’s recent session, 1.02 million shares of the Iovance Biotherapeutics Inc (NASDAQ:IOVA) have been traded, and its beta is 0.68. Most recently the company’s share price was $11.35, and it changed around $0.04 or 0.33% from the last close, which brings the market valuation of the company to $3.17B. IOVA at last check was trading at a discount to its 52-week high of $18.33, offering almost -61.5% off that amount. The share price’s 52-week low was $3.21, which indicates that the recent value has risen by an impressive 71.72% since then. We note from Iovance Biotherapeutics Inc’s average daily trading volume that its 3-month average coming to 9.10 million.
Iovance Biotherapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.29. If we narrow it down even further, the data shows that 0 out of 7 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 0 recommended IOVA as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight. Iovance Biotherapeutics Inc is expected to report earnings per share of -$0.42 for the current quarter.
Iovance Biotherapeutics Inc (NASDAQ:IOVA) trade information
Instantly IOVA has been showing a green trend so far today with a performance of 0.33% on intraday trading today. The performance over the last five days has remained in the red territory. The company’s shares are currently up 39.58% year-to-date, but still down -4.56% over the last five days. On the other hand, Iovance Biotherapeutics Inc (NASDAQ:IOVA) is -26.12% down in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $21.33, which translates to bulls needing to increase their stock price by 46.79% from its current value. Analyst projections state that IOVA is forecast to be at a low of $6 and a high of $40.
Iovance Biotherapeutics Inc (IOVA) estimates and forecasts
Iovance Biotherapeutics Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 243.87 percent over the past six months and at a 25.40% annual growth rate that is well above the industry average of 13.30%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 16.00% in revenue this quarter, and will report an increase of 23.40% in the next quarter. The year-over-year growth rate is expected to be 13,547.60%, up from the previous year.
Consensus estimates provided by 12 financial analysts predict the company will bring in an average of $2.07 million in revenue for the current quarter. 12 analysts expect Iovance Biotherapeutics Inc to make $28.6 million in revenue for the quarter ending Jun 2024. The company’s sales for the same quarters a year ago were $200k and $238k respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 935.00%. Forecasts for the next quarter put sales growth at 11,916.80%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -8.25%.
